MedTrace Logo

Semaglutide Therapy for Alcohol Reduction - Tulsa

NCT05891587 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-12-17

No results posted yet for this study

Summary

The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.

Conditions

Interventions

DRUG

Semaglutide

Semaglutide pen injector

DRUG

Placebo

Saline solution

Sponsors & Collaborators

  • National Institute of Drug Abuse

    collaborator FED

  • Oklahoma State University Center for Health Sciences

    lead OTHER

Principal Investigators

  • William K Simmons, Ph.D. · Oklahoma State University Center for Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-07
Primary Completion
2025-07-30
Completion
2025-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891587 on ClinicalTrials.gov